Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs
Abstract
Aim- We present that chronic hepatitis C virus (HCV) infection is an important source of morbidity and mortality among haemophiliacs. Limited data are available regarding treatment intervention using direct-acting antivirals (DAAs) and theoretical concerns regarding accumulation of drug-associated resistance variants (RAVs) remain. We conducted a pilot study of treatment with telaprevir/pegylated interferon-alfa/ribavirin to evaluate treatment response and the role of lead-in DAA therapy on mutational selection of resistance variants. Methods- Ultra-deep sequence analysis was performed at baseline, 48 hours and 168 hours after treatment initiation. Results- No dominant RAVs were identified at baseline, but low-level RAVs were noted at baseline in all subjects. Viral dynamic models were used to assess treatment responses. The efficacy parameter (ε) for lead-in ranged from 0 to 0.9745 (mean = 0.514). Subsequent addition of telaprevir resulted in a mean efficacy of more than 0.999. This was comparable to subjects who started all three medications simultaneously. A total of 80% achieved SVR. While rapid shifts in the RAV population following DAA initiation were observed, treatment failure associated with A156V was observed in only one patient. Adverse event profiles were similar to that observed in non-haemophilia cohorts. There was no evidence of factor inhibitor formation. There wasmore »
- Authors:
-
[2];
[2]
- University of Cincinnati College of Medicine, Cincinnati, OH (United States)
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
- Publication Date:
- Research Org.:
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
- Sponsoring Org.:
- USDOE; National Institutes of Health (NIH)
- OSTI Identifier:
- 1471325
- Report Number(s):
- LA-UR-14-29029
Journal ID: ISSN 1351-8216
- Grant/Contract Number:
- AC52-06NA25396
- Resource Type:
- Accepted Manuscript
- Journal Name:
- Haemophilia
- Additional Journal Information:
- Journal Volume: 22; Journal Issue: 4; Journal ID: ISSN 1351-8216
- Publisher:
- Wiley
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 59 BASIC BIOLOGICAL SCIENCES; direct-acting antivirals; HCV; haemophilia; resistance-associated variants; treatment response; viral dynamic models
Citation Formats
Sherman, Kenneth E., Ke, Ruian, Rouster, Susan D., Abdel-Hameed, E. A., Park, C., Palascak, Joseph, and Perelson, Alan S. Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs. United States: N. p., 2016.
Web. doi:10.1111/hae.12918.
Sherman, Kenneth E., Ke, Ruian, Rouster, Susan D., Abdel-Hameed, E. A., Park, C., Palascak, Joseph, & Perelson, Alan S. Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs. United States. https://doi.org/10.1111/hae.12918
Sherman, Kenneth E., Ke, Ruian, Rouster, Susan D., Abdel-Hameed, E. A., Park, C., Palascak, Joseph, and Perelson, Alan S. Thu .
"Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs". United States. https://doi.org/10.1111/hae.12918. https://www.osti.gov/servlets/purl/1471325.
@article{osti_1471325,
title = {Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs},
author = {Sherman, Kenneth E. and Ke, Ruian and Rouster, Susan D. and Abdel-Hameed, E. A. and Park, C. and Palascak, Joseph and Perelson, Alan S.},
abstractNote = {Aim- We present that chronic hepatitis C virus (HCV) infection is an important source of morbidity and mortality among haemophiliacs. Limited data are available regarding treatment intervention using direct-acting antivirals (DAAs) and theoretical concerns regarding accumulation of drug-associated resistance variants (RAVs) remain. We conducted a pilot study of treatment with telaprevir/pegylated interferon-alfa/ribavirin to evaluate treatment response and the role of lead-in DAA therapy on mutational selection of resistance variants. Methods- Ultra-deep sequence analysis was performed at baseline, 48 hours and 168 hours after treatment initiation. Results- No dominant RAVs were identified at baseline, but low-level RAVs were noted at baseline in all subjects. Viral dynamic models were used to assess treatment responses. The efficacy parameter (ε) for lead-in ranged from 0 to 0.9745 (mean = 0.514). Subsequent addition of telaprevir resulted in a mean efficacy of more than 0.999. This was comparable to subjects who started all three medications simultaneously. A total of 80% achieved SVR. While rapid shifts in the RAV population following DAA initiation were observed, treatment failure associated with A156V was observed in only one patient. Adverse event profiles were similar to that observed in non-haemophilia cohorts. There was no evidence of factor inhibitor formation. There was no evidence that lead-in provided benefit in terms of response efficacy. Conclusion- Finally, these data support DAA-based therapy in those with inherited bleeding disorders.},
doi = {10.1111/hae.12918},
journal = {Haemophilia},
number = 4,
volume = 22,
place = {United States},
year = {Thu Mar 03 00:00:00 EST 2016},
month = {Thu Mar 03 00:00:00 EST 2016}
}
Free Publicly Available Full Text
Publisher's Version of Record
Other availability
Search WorldCat to find libraries that may hold this journal
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.
Works referenced in this record:
Viral pathogens: VIRAL PATHOGENS
journal, June 2010
- Ragni, M. V.; Sherman, K. E.; Jordan, J. A.
- Haemophilia, Vol. 16
Naturally occurring hepatitis C virus protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV co-infection: Resistance to HCV protease inhibitors
journal, November 2015
- Cao, Ying; Zhang, Yu; Bao, Yi
- Hepatology Research, Vol. 46, Issue 6
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
journal, February 2016
- Zeuzem, Stefan; Hézode, Christophe; Bronowicki, Jean-Pierre
- Journal of Hepatology, Vol. 64, Issue 2
Hepatitis C virus NS3 mutations in haemophiliacs
journal, April 2014
- Lin, M. V.; Charlton, A. N.; Rouster, S. D.
- Haemophilia, Vol. 20, Issue 5
Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling
journal, January 2014
- Rong, Libin; Guedj, Jeremie; Dahari, Harel
- Antiviral Therapy, Vol. 19, Issue 5
A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy
journal, May 2014
- Murata, Masayuki; Furusyo, Norihiro; Ogawa, Eiichi
- Journal of Infection and Chemotherapy, Vol. 20, Issue 5
Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection
journal, August 2015
- Stedman, C. A. M.; Hyland, R. H.; Ding, X.
- Haemophilia, Vol. 22, Issue 2
HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV
journal, January 2005
- Qin, Hongxing; Shire, Norah J.; Keenan, Erica D.
- Blood, Vol. 105, Issue 2
Prevalence and Changes in Hepatitis C Virus Genotypes among Multitransfused Persons with Hemophilia
journal, May 1999
- Eyster, M. Elaine; Sherman, Kenneth E.; Goedert, James J.
- The Journal of Infectious Diseases, Vol. 179, Issue 5
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy
journal, October 1998
- Neumann, A. U.
- Science, Vol. 282, Issue 5386
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
journal, September 2007
- Kieffer, Tara L.; Sarrazin, Christoph; Miller, Janice S.
- Hepatology, Vol. 46, Issue 3
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
journal, February 2013
- Guedj, J.; Dahari, H.; Rong, L.
- Proceedings of the National Academy of Sciences, Vol. 110, Issue 10
Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C
journal, January 2014
- Applegate, Tanya L.; Gaudieri, Silvana; Plauzolles, Anne
- Antiviral Therapy, Vol. 20, Issue 2